[Preparation and functional study of an adenovirus vector expressing human plasminogen kringle 5 gene]

Jian Yang1, Yue-Xiang Wang, Xiao-Qun Guan

  • 1The Key Laboratory of Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China. hysong@shmu.edu.cn

Insights

This study developed a recombinant adenovirus carrying human plasminogen kringle 5 (K5) to inhibit tumor angiogenesis. The Ad-K5 effectively suppressed endothelial cell proliferation and tube formation, showing potential for cancer gene therapy.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Oncology

Context:

  • Tumor angiogenesis is crucial for cancer progression.
  • Endogenous inhibitors like human plasminogen kringle 5 (K5) show anti-angiogenic potential.
  • Adenovirus vectors are utilized for gene delivery in therapeutic strategies.

Purpose:

  • To construct and evaluate a replication-incompetent adenovirus vector (Ad-K5) expressing human plasminogen kringle 5 (K5).
  • To assess the anti-angiogenic effects of Ad-K5 on vascular endothelial cells and tumor cells in vitro.
  • To investigate the potential of Ad-K5 gene therapy for cancer treatment by inhibiting angiogenesis.

Summary:

  • A recombinant adenovirus, Adeno-X-CMV-K5 (Ad-K5), was successfully constructed and propagated.
  • Ad-K5 significantly inhibited the proliferation, differentiation, and tube formation of human umbilical vein endothelial cells (ECV304) in a dose-dependent manner.
  • Ad-K5 did not affect the proliferation of human breast carcinoma cells (MDA-MB-231), indicating specificity.

Impact:

  • Adenovirus-mediated delivery of human plasminogen kringle 5 demonstrates significant anti-angiogenic properties.
  • This approach offers a potential therapeutic strategy for managing cancers by targeting tumor angiogenesis.
  • Further research into Ad-K5 gene therapy could lead to novel treatments for angiogenesis-dependent diseases.

Related Concept Videos